Cardiovascular Disease: New Perspectives in the Light of a Pandemic
7 July 2020
10 July 2020
Heart attacks, strokes and chronic heart failure are among the most serious medical and social problems in the modern world. According to data from the World Health Organization, cardiovascular disease is one of the top causes of death worldwide, with around 17 million people dying each year as a result of diseases related to the cardiovascular system. The issue of chronic heart failure is made even more pressing by the severe progression of the disease and the significant treatment costs. Furthermore, CVD is not perceived as a serious threat to life in the mind of the public (as opposed to cancer, for example) and the medical community sees social attitudes towards this group of illnesses as an obstacle. The situation concerning the spread of the new coronavirus infection, however, has forced society to look at the relevance of CVD from a new perspective, given the increased risk to those suffering from heart and blood vessel diseases. All over the world, especially in Russia, doctors paid special attention to patients suffering from heart disease during the early stages of the spread of the virus. In these cases, the SARS-CoV-2 infection significantly worsens the condition of the patient’s heart and blood vessels, complicating the treatment of patients with chronic heart failure and increasing mortality rates. What are the barriers and opportunities when it comes to achieving the goals of the national Healthcare project in the fight against cardiovascular disease within the framework of a modern governance model? How does the difficulty of treatment during an epidemic affect the incidence of chronic heart failure? What changes will be made to the Fight Against Cardiovascular Disease federal project? What state support measures are in place in the fight against CVD? How can public attitudes towards the issue of CVD be changed and how can a behavioural model for preventing CVD be implemented?
AstraZeneca Pharmaceuticals LLC
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.Irina Panarina
General director of AstraZeneca in Russia and Eurasia
Since may, 2017 Irina has been holding the position of general director of AstraZeneca in Russia and Eurasia.
Irina is responsible for the company business at the level of Russia and Eurasia region. She is also in charge of AstraZeneca Russia.
Irina Panarina has been working in AstraZeneca since 2009. In October, 2015 Irina joined Russian team as Director of Cardiology and Diabetes business unit.
Before joining AstraZeneca Russia Irina Panarina held the position of general director of AstraZeneca Ukraine.
Prior to joining AstraZeneca, Irina held regional positions in the GSK Pharma's headquarter in London, the UK.
Irina Panarina has a vast experience in marketing, product portfolio management and team development.
Irina Panarina has graduated from Newcastle University and London South Bank University. She has also completed an MBA in INSEAD Business School.
Since February 2018, Irina Panarina has been a member of the General Council of the All Russia Public Organization Business Russia. In March 2018, she was appointed as Business Russia Ambassador to Sweden. In December 2019, Irina Panarina joined the Coordinating Council of Business Russia.